$BIIB
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$BIIB
Biogen Inc.
$BIIBNASDAQHealthcareLarge-Cap
Biogen develops and commercializes therapies for neurological diseases including multiple sclerosis and Alzheimer's.
Market Cap
$25.0B
Revenue (TTM)
$9.5B
-3.0%
Net Income (TTM)
$1.8B
-10.0%
EPS (TTM)
$12.50
P/E Ratio
14.0
Dividend Yield
0.0%
52-Week Range
$150-$280
Beta
0.42
Dimension Scores
Fundamental
56Technical
54Sentiment
58Risk / Reward
62Momentum
52Financial Health
Profitability
61moderate
Growth
55moderate
Liquidity
70strong
Solvency
58moderate
Efficiency
54moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $BIIB
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.